Assessing the relationship between antigenicity and immunogenicity of human rabies vaccines when administered by intradermal route

Figures & data

Figure 1 Correlation between antigenic load by day 7 versus GMC by day 14 (r = 0.289, p > 0.230).

Figure 2 Correlation between antigenic load by day 28 versus GMC by day 90 (r = 0.140, p > 0.568).

Table 1 Details of regimens, schedules, cohorts and vaccines

Regimen	Schedule	Total cohorts	Vaccines (cohorts)
Updated TRC	(2-2-2-0-2)	5	Rabipur (2)
			Verorab (1)
			Indirab (2)
TRC	(2-2-2-0-1-1)	7	Rabipur (4)
			Verorab (3)
8 site	(8-0-4-0-1-1)	2	Rabipur (2)
4 site	(4-0-2-0-1-1 & 4-4-4-0-1-1)	4	Rabipur (2)
			Verorab (1)
			MIRV (1)
KIMS	(2-2-2-2-2)	1	Rabipur (1)

Note: RVNA Method: RFFIT (15 cohorts); MNT (4 cohorts).

Table 2 Details of vaccine cohorts, ID regimens, antigenic loads and immune response

Cohort	Vaccine	Potency/ID dose	ID Schedule	Number of Subjects	Antigenic load (Day 7)	GMC (Day 14)	Antigenic load (Day 28)	GMC (Day 90)	Type of RVNA analysis
1	Rabipur7	0.55	4-0-2-0-1-1	86	3.30	20.50	3.85	2.39	RFFIT
2	Indirab19	0.55	2-2-2-0-2	55	3.30	5.40	4.40	3.66	RFFIT
3	Rabipur8	0.60	2-2-2-0-1-1	65	3.60	7.13	4.20	2.27	MNT
4	MIRV9	0.32	4-4-4-0-1-1	19	3.84	9.88	4.16	3.57	RFFIT
5	Rabipur10	0.70	2-2-2-0-1-1	81	4.20	9.07	4.90	3.67	RFFIT
6	Rabipur11	0.76	2-2-2-0-1-1	25	4.56	6.70	5.32	5.10	MNT
7	Rabipur19	0.91	2-2-2-0-2	54	5.46	4.75	7.28	3.30	RFFIT
8	Rabipur12	0.92	2-2-2-0-1-1	59	5.52	28.50	6.44	3.00	RFFIT
9	Rabipur13	0.94	2-2-2-2-2	45	5.64	4.17	9.43	4.79	RFFIT
10	Rabipur14	0.94	2-2-2-0-1-1	49	5.64	4.30	6.58	6.70	RFFIT
11	Rabipur17	0.99	2-2-2-0-2	81	5.94	5.83	7.92	7.20	RFFIT
12	Rabipur15	0.75	4-0-4-0-1-1	15	6.00	7.20	6.75	2.70	RFFIT
13	Indirab18	1.14	2-2-2-0-2	68	6.84	4.46	9.12	4.30	RFFIT
14	Rabipur15	0.75	8-0-4-0-1-1	15	9.00	5.40	9.75	2.70	RFFIT
15	Rabipur16	0.78	8-0-4-0-1-1	39	9.36	10.20	10.14	8.50	MNT
16	Rabipur16	1.56	2-2-2-0-1-1	43	9.36	6.80	10.92	5.80	MNT
17	Verorab7	1.78	4-0-2-0-1-1	87	10.68	26.10	12.46	2.75	RFFIT
18	Verorab18	2.24	2-2-2-0-2	66	13.44	4.67	17.92	4.75	RFFIT
19	Verorab12	2.32	2-2-2-0-1-1	59	13.92	28.90	16.24	2.70	RFFIT

Note: GMC, Geometric mean concentration; RFFIT, Rapid fluorescent focus inhibition test; MNT, Mouse neutralization test.

Ambrozaitis A, Laiskonis A, Balciuniene L, Banzhoff A, Malerczyk C. Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): An immunogenic, cost-effective and practical regimen. Vaccine 2006; 24:4116 - 4121

 PubMed Web of Science ®Google Scholar

A report on “A comparative phase III, randomized (1:1) single blind study to evaluate the safety and immunogenicity of rabies vaccines (Indirab vs. reference vaccine) reconstituted with 1 mL diluent each, administered intradermally using simulated post exposure updated Thai Red Cross regimen in healthy volunteers” 2009; Hyderabad, India Bharath Biotech International Ltd.

 Google Scholar

Charanasri U, Kingnate D, Meesomboon V, Samuthananon P, Chaeychomsri W. Intradermal simulated rabies post-exposure prophylaxis using purified chick embryo rabies vaccine. J Med Assoc Thai 1992; 75:639 - 642

 PubMedGoogle Scholar

Ubol S, Phanuphak P. An effective economical intradermal regimen of human diploid cell rabies vaccination for post-exposure treatment. Clin Exp Immunol 1986; 63:491 - 497

 PubMed Web of Science ®Google Scholar

Suntharasamai P, Chaiprasithikul P, Wasi C, Supanaranond W, Auewarakul P, Chanthavanich P. A simplified and economical intradermal regimen of purified chick embryo cell rabies vaccine for post-exposure prophylaxis. Vaccine 1994; 12:508 - 512

 PubMed Web of Science ®Google Scholar

Madhusudana SN, Prem Anand N. Response to purified chick embryo cell rabies vaccine administered intra-dermally for post-exposure prophylaxis. The Nat Med J India 1997; 10:115 - 116

 PubMed Web of Science ®Google Scholar

Briggs DJ, Banzhoff A, Nicolay U, Sirikwin S, Dumavibhat B, Tongswas S. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified vero cell rabies vaccine. Bull World Health Organ 2000; 78:693 - 698

 PubMed Web of Science ®Google Scholar

Sudarshan MK, Madhusudana SN, Mahendra BJ, Ashwath Narayana DH, Ananda Giri MS, Popova O. Evaluation of a new five-injection, two-site, intradermal schedule for purified chick embryo cell rabies vaccine: A randomized, open-label, active-controlled trial in healthy adult volunteers in India. Current Therapeutic Res 2005; 66:323 - 334

 PubMed Web of Science ®Google Scholar

Madhusudana SN, Sanjay TV, Mahendra BJ, Sudarshan MK, Ashwath Narayana DH, Ananda Giri MS. Comparison of safety and immunogenicity of purified chick embryo cell rabies vaccine (PCEV) and purified vero cell rabies vaccine (PVRV) using the Thai Red Cross intradermal regimen at a dose of 0.1 ml. Hum Vaccin 2006; 2:200 - 204

 PubMed Web of Science ®Google Scholar

A report on “A clinical evaluation of safety and immunogenicity of purified chick embryo cell rabies vaccine (PCECV), administered intradermally using updated Thai Red Cross regimen in animal bite cases” 2007; India Novartis Vaccines

 Google Scholar

Wilde H, Khawplod P, Hemachudha T, Sitprija V. Postexposure treatment of rabies infection: can it be done without immunoglobulin?. CID 2000; 34:477 - 480

 Web of Science ®Google Scholar

A report on “A comparative, multi center Phase III, randomized (1:1) double blind study to evaluate the safety and immunogenicity of PVRV (Indirab vs. reference vaccine) administered intradermally using simulated updated Thai Red cross regimen in healthy volunteers” 2009; Hyderabad, India Bharath Biotech International Ltd.

 Google Scholar

Madhusudana SN, Prem Anand N, Shamsundar R. Evaluation of two intradermal vaccination regimens using purified chick embryo cell vaccine for postexposure prophylaxis of rabies. Nat Med J India 2001; 14:145 - 147

 PubMed Web of Science ®Google Scholar